Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For relapsed or resistant DLBCL, odronextamab produced positive results.

2.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

3.

Even when they are not paying attention, children are still learning.

4.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

5.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot